Nachrichten zur Biogen Inc. Aktie

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact…

LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period

Stockholm, Sweden, November 7, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…

Biogen Appoints Monish Patolawala to its Board of Directors

Biogen Appoints Monish Patolawala to its Board of Directors…

Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

Biogens (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis…

Earnings playbook: How to trade the biggest reports this week, including Disney

More than 45 S&P 500 names are slated to report this week, including Disney, Biogen and D.R. Horton.…

Eilt: Globaler Lizenzdeal voraus - Neuer 407% Biotech Aktientip nach 31.205% mit Amgen und 134.452% mit Biogen ($BIIB)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 238% Kursziel 24M: 1,50 EUR Kurschance: 407%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,296 EUR 52W Hoch:…

Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy

…

SCLX: An Innovative and Growing Pain Management Company

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on…

More convenient form of breakthrough Alzheimers drug Leqembi shows promising results in study

Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the…

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake…

: Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.…

Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug

…

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data…

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its…

Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

FDA approves Biogen’s biosimilar to Roches arthritis drug Actemra

…

: Biogen gets FDA approval for biotech treatment similar to Roche’s Actemra

Biogen Inc. BIIB said late Friday the Food and Drug Administration approved its biosimilar version of Roche CH:ROG‘s arthritis treatment…

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug…

Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares

…

Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester

Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…

Biogen Completes Acquisition of Reata Pharmaceuticals

CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of…

Reata shareholders clear buyout deal with Biogen

…

IBD (Ulcerative Colitis and Crohns Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester

Leading IBD (Ulcerative Colitis and Crohns Disease) Treatment Market players include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol…

Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment

Biogen Inc. BIIB shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis…

Biotech Report: Evotec (EVT) klettern, MorphoSys (MOR) und Qiagen (QIA) behauptet

Biotech-Aktien zeigen sich im deutschen Handel erneut fester. Unter anderem können Evotec und Qiagen zulegen. An der Wall Street…

Beschäftigte des US-Biotechnologiekonzerns Biogen in Baar zittern um ihren Arbeitsplatz

Der Medikamentenhersteller Biogen streicht weltweit mehr als jede neunte Stelle. Da vorab Funktionen innerhalb der Zentrale verschwinden sollen, geht am…

Biogen sticht Sanofi aus – um 50 Cent

Große Pharma- und Biotech-Unternehmen befinden sich auf der Suche nach interessanten Übernahmezielen. Vor Kurzem ist Biogen fündig geworden und hat…

Biogen/ Sage expected to hike price for new depression drug after narrow label

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues

Denalis (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen....…

XETR : US09062X1037: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

XFRA : ZERTIFIKATEBOERSE RESUMPTION OF UNDERL.: US09062X1037

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US09062X1037 SIND AB 13:41 CET WIEDER IN DEN HANDEL AUFGENOMMEN. ALL STRUCTURED PRODUCTS WITH UNDERLYING US09062X1037…

XFRA : IDP: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug

The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for…

Biogen, Sage face uphill battle with postpartum depression pill

...By Bhanvi Satija and Mariam Sunny (Reuters) - The U.S. drug......…

XETR : US09062X1037: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: US09062X1037

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING US09062X1037 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING US09062X1037…

XFRA : IDP: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XETR : INSTRUMENT_SUSPENSION - US09062X1037

Instrument ID [2506448] (IDP - US09062X1037) suspended...…

Sage and Biogen receive FDA approval for PPD therapy

Said to be the first and only oral, once-a-day, 14-day treatment, ZURZUVAE can provide quick improvements in depressive symptoms for…

Biogen: FDA Approves First Oral Treatment For Postpartum Depression

WESTON (dpa-AFX) - The U.S. Food and Drug Administration approved Zurzuvae (zuranolone) 50 mg for adults with postpartum depression, Sage…

Biogen, Sage Pill Is First Cleared for Postpartum Depression

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression

...(Adds context throughout) Aug 4 (Reuters) - The U.S. Food and Drug......…

US FDA approves Biogen-Sage Therapeutics pill for clinical depression

...Aug 4 (Reuters) - The U.S. Food and Drug Administration on Friday......…

Sage, Biogen postpartum depression pill zuranolone wins FDA approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Eilt: Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 212% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. 212% Biotech Hot Stock nach 134.452% mit Biogen 03.08.23 08:02AC Research London (www.aktiencheck.de , Anzeige) Link…

dpa-AFX ProFeed